Harrow Health, Inc.
HROWNASDAQHealthcare● Active
$32.84
$-0.36(-1.07%)
Market Cap$1.2B
P/E Ratio—
52W High$54.85
52W Low$27.76
Harrow Health, Inc. (HROW) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HROW · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.63
Est. -$0.43 · -46.5%
Revenue
$0.04B
Est. $0.05B · -15.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
HROW reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.23 | — | — | — | $0.07B | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.43 | -$0.63 | -46.5% | $0.04B | $0.05B | -15.7% |
| ▼ Q1 FY2026 | Mar 2, 2026 | $0.40 | $0.26 | -35.0% | $0.09B | $0.09B | -1.0% |
| ▲ Q4 FY2025 | Nov 10, 2025 | $0.22 | $0.33 | +50.0% | $0.07B | $0.09B | -18.6% |
| ▼ Q3 FY2025 | Aug 11, 2025 | $0.31 | $0.24 | -23.4% | $0.06B | $0.07B | -13.8% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.02 | -$0.38 | -2000.0% | $0.05B | $0.07B | -29.5% |
| ▲ Q1 FY2025 | Mar 27, 2025 | $0.11 | $0.25 | +127.3% | $0.07B | $0.06B | +14.4% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.05 | -$0.12 | -140.0% | $0.05B | $0.06B | -16.6% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.63
EPS Est.
-$0.43
EPS Surpr.
-46.5%
Revenue
$0.04B
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
$0.26
EPS Est.
$0.40
EPS Surpr.
-35.0%
Revenue
$0.09B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
$0.33
EPS Est.
$0.22
EPS Surpr.
+50.0%
Revenue
$0.07B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
$0.24
EPS Est.
$0.31
EPS Surpr.
-23.4%
Revenue
$0.06B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.38
EPS Est.
$0.02
EPS Surpr.
-2000.0%
Revenue
$0.05B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
$0.25
EPS Est.
$0.11
EPS Surpr.
+127.3%
Revenue
$0.07B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.12
EPS Est.
-$0.05
EPS Surpr.
-140.0%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.64 | $1.77 | $1.89 | 1 |
| Q3 FY2028 | $0.82 | $0.89 | $0.95 | 1 |
| Q2 FY2028 | $0.34 | $0.37 | $0.39 | 1 |
| Q1 FY2028 | $-0.18 | $-0.17 | $-0.16 | 1 |
| Q4 FY2027 | $0.96 | $1.03 | $1.10 | 1 |
| Q3 FY2027 | $0.56 | $0.61 | $0.65 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.3B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.1B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -46.5% | $38.23 | $38.04 | -0.50% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -35.0% | $54.18 | $53.59 | -1.09% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +50.0% | $33.93 | $34.14 | +0.62% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -23.4% | $34.43 | $33.74 | -2.00% |
| ▼ Q2 FY2025 | May 8, 2025 | -2000.0% | $24.59 | $23.59 | -4.07% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +127.3% | $27.65 | $27.87 | +0.80% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -140.0% | $49.91 | $51.80 | +3.79% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +48.0% | $22.72 | $21.98 | -3.26% |
Q2 FY2026-0.50%
Report Date
May 11, 2026
EPS Beat/Miss
-46.5%
Price Before
$38.23
Price After
$38.04
Q1 FY2026-1.09%
Report Date
Mar 2, 2026
EPS Beat/Miss
-35.0%
Price Before
$54.18
Price After
$53.59
Q4 FY2025+0.62%
Report Date
Nov 10, 2025
EPS Beat/Miss
+50.0%
Price Before
$33.93
Price After
$34.14
Q3 FY2025-2.00%
Report Date
Aug 11, 2025
EPS Beat/Miss
-23.4%
Price Before
$34.43
Price After
$33.74
Q2 FY2025-4.07%
Report Date
May 8, 2025
EPS Beat/Miss
-2000.0%
Price Before
$24.59
Price After
$23.59
Q1 FY2025+0.80%
Report Date
Mar 27, 2025
EPS Beat/Miss
+127.3%
Price Before
$27.65
Price After
$27.87
Q4 FY2024+3.79%
Report Date
Nov 13, 2024
EPS Beat/Miss
-140.0%
Price Before
$49.91
Price After
$51.80
Q3 FY2024-3.26%
Report Date
Aug 7, 2024
EPS Beat/Miss
+48.0%
Price Before
$22.72
Price After
$21.98
Avg Beat Reaction-0.61%
Avg Miss Reaction-0.77%
Beat Rate3 / 8 quarters
Largest Move-4.07% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HROW ends December
Harrow Health, Inc. (HROW) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.63 — missing the analyst consensus of $-0.43 by -46.5%. The next HROW earnings date is expected around September 1, 2026.
Each quarter, investors track HROW earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HROW revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HROW's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HROW earnings · 5 questionsHarrow Health, Inc.'s next earnings report is expected around September 1, 2026. HROW typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HROW historically reports after market close (AMC).
HROW earnings datewhen is HROW earningsHROW next earnings datewhen does HROW report earningsHROW earnings calendar
▸ Source: FMP · Harrow Health, Inc. SEC filings · US GAAP · Harrow Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026